The market size of the Global Polycystic Ovary Syndrome (PCOS) Treatment Market in the year 2021 is valued at 3.41 billion and is predicted to reach 5.26 billion by the year 2030 at an 5.13% CAGR during the forecast period.
Women of childbearing age frequently have polycystic ovarian syndrome (PCOS), a hormonal disorder. Menstrual cycles that are irregular or prolonged, as well as excessive levels of male hormones, might be caused by PCOS. There is no known treatment for PCOS, but several medications control its symptoms and menstrual cycle. An increase in PCOS prevalence, an increase in patient population knowledge, and an increase in the use of combination therapy are the major factors driving the growth of the polycystic ovarian syndrome treatment market. Advances in PCOS screening technology, the rise in demand for PCOS medications, and the accessibility of PCOS treatment also impact the market's expansion. However, it is anticipated that market growth will be constrained by the lack of approved treatments and PCOS's uncertain pathophysiology and etiology.
Additionally, during the projected period, the unrealized potential of developing economies presents lucrative market growth opportunities. As the prevalence of polycystic ovarian syndrome (PCOS) rises, so is the need for treatment. However, the absence of specialized treatment for PCOS disease is anticipated to impede market expansion.
The polycystic ovary syndrome (PCOS) treatment market is segmented on the drug class and distribution channel. Based on drug class, the market is segmented into oral contraceptives, insulin sensitizing agents, antidepressants, ornithine decarboxylase inhibitors, aromatase inhibitors & SERMs and diuretics. Based on distribution channel, polycystic ovary syndrome (PCOS) treatment market is segmented into hospital pharmacies, drug stores/OTC, e-commerce and clinics.
Based on drug class, the insulin sensitizing agents segment is accounted as a major contributor to the polycystic ovary syndrome (PCOS) treatment market.
Based on drug class, the market is segmented into oral contraceptives, insulin-sensitizing agents, antidepressants, ornithine decarboxylase inhibitors, aromatase inhibitors & SERMs and diuretics. The insulin-sensitizing agent's category grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the anticipated time. Numerous items are offered for sale, including Glucophage X.R. (Metformin) and other items that contain Troglitazone, Rosiglitazone, and Pioglitazone. Metabolic dysfunction in PCOS may cause an overproduction of androgen, impacting insulin secretion and raising the risk of diabetes. As a result, insulin-sensitizing drugs are crucial for therapeutics because they balance hormone levels, lower insulin levels, and reduce ovarian androgen production.
The e-commerce retailing segment witnessed growth at a rapid rate.
Based on the distribution channel, the polycystic ovary syndrome (PCOS) treatment market is segmented into hospital pharmacies, drug stores/OTC, e-commerce and clinics. The e-commerce category is anticipated to grow significantly over the forecast period because more people prefer buying medicines online over traditional means, more people are aware of online sources, and more people are using the internet.
The Asia Pacific polycystic ovary syndrome (PCOS) treatment market holds a significant revenue share in the region.
The Asia Pacific polycystic ovary syndrome (PCOS) treatment market is expected to register the highest market share in revenue shortly. The market will expand due to the rising acceptance of products for treating polycystic ovarian syndrome and increased knowledge of the treatment. The development of the R&D sector, the expansion of the target population, the growth of healthcare reforms, and technological developments in the healthcare industry all contribute to the market's expansion. Additionally, North America is anticipated to expand at a significant rate over the course of the forecast period. Factors like the increased focus of major manufacturers on growing their geographic presence in developing Asia-Pacific nations to seize a large population base, high growth opportunities in the market, and high disposable incomes are also anticipated to propel the growth of the market in the region.
The key players in the polycystic ovary syndrome (PCOS) treatment market have shifted their focus toward product manufacturing and are initiating significant strategies such as mergers, acquisitions, and joint ventures of major and domestic players to enhance their product portfolio and strengthen their global market footprint. Some major key players in the polycystic ovary syndrome (PCOS) treatment market are Novartis AG, Sanofi, Teva Pharmaceutical Industries Limited, Merck & Co., Inc. (Merck group), AstraZeneca plc., Bayer AG. Abbott, Pfizer, Inc, Bristol-Myer Squibb Company, Ferring Pharmaceuticals, Inc., Johnson and Johnson, Mylan N.V., Allergan plc., GlaxoSmithKline, Lupin Pharmaceuticals, AbbVie, Takeda, BIOCAD Global, Blairex Laboratories Inc and Agile Therapeutics.